ReShape Lifesciences Announces Participation in the A.G.P Virtual MedTech Conference

Rhea-AI Summary

ReShape Lifesciences (Nasdaq: RSLS) announced participation in one-on-one meetings with institutional investors at the A.G.P. Virtual MedTech Conference on September 21, 2022. The company, focused on weight loss and metabolic health, offers various solutions, including the FDA-approved Lap-Band® Program and the ReShape Vest™ System. For more information, interested investors can contact their A.G.P. representative.

Positive

• Participation in a reputable virtual conference may enhance investor relations.
• Offering a range of innovative products in the obesity treatment sector.

Negative

• None.

SAN CLEMENTE, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer and Tom Stankovich, Chief Financial Officer, will be participating in one-on-one meetings with institutional investors during the A.G.P. Virtual MedTech Conference, taking place Thursday, September 21, 2022.

Investors participating in the virtual conference who are interested in meeting with ReShape’s management team should contact their A.G.P. representative.

About ReShape Lifesciences™
ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. Reshapecare™ is a virtual weight-management program that supports lifestyle changes for all weight-loss patients led by board certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. For more information, please visit www.reshapelifesciences.com,

CONTACTS
ReShape Lifesciences Investor Contact:
Thomas Stankovich
Chief Financial Officer
949-276-6042
ir@ReShapeLifesci.com

Investor Relations Contact:
Rx Communications Group
Michael Miller
(917)-633-6086
mmiller@rxir.com

FAQ

What event is ReShape Lifesciences participating in on September 21, 2022?

ReShape Lifesciences is participating in the A.G.P. Virtual MedTech Conference.

Who from ReShape Lifesciences will attend the MedTech Conference?

Paul F. Hickey, President and CEO, and Tom Stankovich, CFO, will attend.

What products does ReShape Lifesciences offer for weight loss?

ReShape Lifesciences offers the FDA-approved Lap-Band® Program and the ReShape Vest™ System, among other solutions.

How can investors meet with ReShape Lifesciences management during the conference?

Investors interested in meetings should contact their A.G.P. representative.